Quick Answer
Aquestive Therapeutics, Inc. reported Diluted EPS of $0.78 per share (loss) for fiscal year 2025.
Aquestive Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.78 | -52.9% |
| 2024 | -$0.51 | -292.3% |
| 2023 | -$0.13 | +88.4% |
| 2022 | -$1.12 | +39.5% |
| 2021 | -$1.85 | -11.4% |
| 2020 | -$1.66 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.14 | -7.7% | +0.0% |
| June 30, 2025 | -$0.14 | -366.7% | +41.7% |
| March 31, 2025 | -$0.24 | -41.2% | -84.6% |
| September 30, 2024 | -$0.13 | -333.3% | -333.3% |
| June 30, 2024 | -$0.03 | +70.0% | +82.4% |
| March 31, 2024 | -$0.17 | -254.5% | -466.7% |
| September 30, 2023 | -$0.03 | +87.0% | +70.0% |
| June 30, 2023 | -$0.10 | +72.2% | -190.9% |
- Aquestive Therapeutics, Inc. showed a decrease of -52.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Aquestive Therapeutics, Inc.’s diluted eps has grown by 53.0% (from $1.66 per share (loss) to $0.78 per share (loss)).
- The most recent figure is from Aquestive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: